Tranylcypromine — Membership Pricing

Other medications in Mental Health

• Trazodone
• Triazolam
• Trifluoperazine
• Valproate
• Varenicline
• Venlafaxine
• Vilazodone
• Vortioxetine

What Tranylcypromine is approved for (FDA label)

Tranylcypromine tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants.

Source: Read the full FDA label on DailyMed. Label effective date: July 22, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Tranylcypromine (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE WARNING: SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Tranylcypromine tablets are not approved for use in pediatric patients. ( 5.1 , 8.4 ) Excessive consumption of foods or beverages with significant tyramine content or certain drugs can precipitate hypertensive crisis. Monitor blood pressure, allow for medication free intervals, and advise patients to avoid foods and beverages with high tyramine content. ( 5.2 , 7.1 , 7.2 ) Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Tranylcypromine tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . Hypertensive Crisis with Significant Tyramine Use Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with tranylcypromine tablets or after tranylcypromine tablets discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals between administration of tranylcypromine tablets and interacting drugs.

Source: FDA prescribing information (DailyMed). Set ID: 83942f11-e10c-4c2d-ad78-880e1886064d. SPL document ID: 57321a72-7260-30d4-e063-6394a90a3fb3. Label effective date: July 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tranylcypromine (FDA label)

Tablets containing tranylcypromine sulfate equivalent to 10 mg tranylcypromine are round, red, film-coated, and debossed on one side with "10" and plain on the other side. Tablets: 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 83942f11-e10c-4c2d-ad78-880e1886064d. SPL document ID: 57321a72-7260-30d4-e063-6394a90a3fb3. Label effective date: July 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tranylcypromine (FDA label)

The following adverse reactions are described in greater detail in other sections: Suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] Hypertensive crisis and hypertension [see Warnings and Precautions (5.2) ] Serotonin syndrome [see Warnings and Precautions (5.3) ] Activation of mania/hypomania [see Warnings and Precautions (5.4) ] Hypotension [see Warnings and Precautions (5.5) ] Hypotension and hypertension during anesthesia and perioperative care [see Warnings and Precautions (5.6) ] Discontinuation syndrome [see Warnings and Precautions (5.8) ] Persistence of MAO inhibition after discontinuation [see Warnings and Precautions (5.9) ] Hepatotoxicity [see Warnings and Precautions (5.10) ] Seizures [see Warnings and Precautions (5.11) ] Hypoglycemia in diabetic patients [see Warnings and Precautions (5.12) ] Aggravation of coexisting symptoms of depression [see Warnings and Precautions (5.13) ] Adverse effects on the ability to drive and operate machinery [see Warnings and Precautions (5.14) ] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Based on clinical trial data, the most common adverse reactions to tranylcypromine were dry mouth, dizziness, insomnia, sedation, and headache (>30%) and overexcitement, constipation, blurred vision, and tremor (>10%).

Source: FDA prescribing information (DailyMed). Set ID: 83942f11-e10c-4c2d-ad78-880e1886064d. SPL document ID: 57321a72-7260-30d4-e063-6394a90a3fb3. Label effective date: July 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tranylcypromine (FDA label)

Concomitant use or use in rapid succession with other MAOIs; selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitors; tricyclic antidepressants; sympathomimetic drugs; and numerous other drugs. See Full Prescribing Information for the full list of contraindicated products ( 4.1 , 7.1 ) Pheochromocytoma, other catecholamine-releasing paraganglioma ( 4.2 ) 4.1 Combination with Certain Drugs Concomitant use of tranylcypromine tablets or use in rapid succession with the products in Table 1 is contraindicated.

Source: FDA prescribing information (DailyMed). Set ID: 83942f11-e10c-4c2d-ad78-880e1886064d. SPL document ID: 57321a72-7260-30d4-e063-6394a90a3fb3. Label effective date: July 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tranylcypromine (FDA label)

Activation of Mania/Hypomania : May be precipitated by antidepressant treatment in patients with bipolar disorder. Screen patients prior to treatment ( 5.4 ) Hypotension (including syncope) : Monitor patients and adjust tranylcypromine tablets dosage or concomitant medication as necessary ( 5.5 ) Hypotension and Hypertension during Anesthesia and Perioperative Care : If possible, discontinue tranylcypromine tablets prior to elective surgery ( 5.6 ) Hepatitis and Elevated Liver Enzymes : Monitor accordingly ( 5.10 ) 5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients.

Source: FDA prescribing information (DailyMed). Set ID: 83942f11-e10c-4c2d-ad78-880e1886064d. SPL document ID: 57321a72-7260-30d4-e063-6394a90a3fb3. Label effective date: July 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tranylcypromine (FDA label)

See Full Prescribing Information for a list of products, foods and beverages that can interact with tranylcypromine tablets ( 7 ) 7.1 Clinically-Significant Drug Interactions Tables 3 and 4 lists drug classes and individual products, respectively, with a potential for interaction with tranylcypromine tablets, describes the predominant observed or anticipated risks, and provides advice on concomitant use. Given serious adverse reactions with multiple agents, patients should avoid taking over-the-counter medications or dietary supplements without prior consultation with a healthcare provider able to provide advice on the potential for interactions. Time to Start Tranylcypromine Tablets after Discontinuation of a Contraindicated Drug For products that are contraindicated with tranylcypromine tablets, a time period of 4 to 5 half-lives of the other product or any active metabolite should elapse before starting treatment with tranylcypromine tablets.

Source: FDA prescribing information (DailyMed). Set ID: 83942f11-e10c-4c2d-ad78-880e1886064d. SPL document ID: 57321a72-7260-30d4-e063-6394a90a3fb3. Label effective date: July 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.